- Zacks•5 days ago
Shares of Array BioPharma Inc. (ARRY) slipped 2.30% after the company announced that it has withdrawn its new drug application (NDA) for its pipeline candidate, binimetinib, from the FDA's Division of Oncology Products 2.
- Motley Fool•5 days ago
A setback this week illustrates the challenges, but Array still has plenty of opportunity.
- TheStreet.com•7 days ago
Here's how to trade six of the most active names on the market this afternoon.
ARRY : Summary for Array BioPharma Inc. - Yahoo Finance
Array BioPharma Inc. (ARRY)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
|Bid||9.33 x 300|
|Ask||9.62 x 300|
|Day's Range||9.16 - 9.58|
|52 Week Range||2.60 - 13.40|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-14.24|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|